The French Food Safety Agency (ANSES) has developed an attenuated strain of the African swine fever (ASF) virus, derived from the Georgia 2007/1 strain, which is circulating in the European Union. This new strain causes only mild symptoms in pigs, with a much higher survival rate compared to the original strain. The vaccine, which can be administered both intramuscularly and orally, is under further testing for safety and efficacy. It is not produced through genetic manipulation, which may facilitate its authorization for use in the natural environment, particularly for vaccinating wild boars in Western Europe. ANSES has filed a patent for the vaccine.